SARS-CoV-2

Showing 26 - 50 of 246

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Immunity to Infection in Healthy Participants and Cancer

Recruiting
  • Influenza
  • +3 more
  • Biological sample collection
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hopsital Tuebingen
Mar 31, 2023

SARS-CoV-2 Trial in Herston (Glycovax-002)

Not yet recruiting
  • SARS-CoV-2
  • Glycovax-002
  • Herston, Queensland, Australia
    Q-Pharm Pty Ltd
Apr 3, 2023

Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test

Not yet recruiting
  • SARS-CoV-2
  • +3 more
  • LumiraDx SARS-CoV-2 & Flu A/B
  • Cullman, Alabama
    Cullman Clinical Trials
Mar 16, 2023

SARS-CoV-2, COVID-19 Trial in Palo Alto, Seattle

Active, not recruiting
  • SARS-CoV-2
  • COVID-19
    • Palo Alto, California
    • +1 more
    Mar 13, 2023

    SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution)

    Recruiting
    • SARS-CoV-2
    • SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
    • Saline solution
    • Bengbu, Anhui, China
      First Affiliated Hospital Bengbu Medical College
    Feb 26, 2023

    Covid Pandemic on the Patient in Need of an Intervention

    Not yet recruiting
    • Surgery Department, Hospital
    • +4 more
      • (no location specified)
      Feb 20, 2023

      LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B

      Not yet recruiting
      • SARS-CoV-2
      • +4 more
      • LumiraDx SARS-CoV-2 Ag Ultra
      • LumiraDx SARS-CoV-2 & Flu A/B
      • DeLand, Florida
        Hillcrest Medical Research
      Feb 6, 2023

      Israel Clalit Health Services

      Not yet recruiting
      • SARS-CoV-2
      • COVID-19
      • (no location specified)
      Jan 26, 2023

      SARS-CoV-2 Trial in Winston-Salem, San Antonio (ADM03820, Placebo)

      Active, not recruiting
      • SARS-CoV-2
      • Winston-Salem, North Carolina
      • +1 more
      Feb 1, 2023

      Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2 Trial in Belgium, Germany (CVnCoV Vaccine, Placebo)

      Completed
      • Severe Acute Respiratory Syndrome
      • +3 more
      • CVnCoV Vaccine
      • Placebo
      • Ghent, Belgium
      • +3 more
      Apr 29, 2022

      SARS-CoV-2, Influenza, RSV Trial in Australia, United Kingdom, United States (mRNA-1010, mRNA-1345, mRNA-1273.214)

      Recruiting
      • SARS-CoV-2
      • +2 more
      • mRNA-1010
      • +4 more
      • DeLand, Florida
      • +29 more
      Jan 23, 2023

      SARS-CoV-2 Trial in Worldwide (AZD7442)

      Recruiting
      • SARS-CoV-2
      • Long Beach, California
      • +34 more
      Jan 18, 2023

      COVID-19, SARS-CoV-2 Trial in London (COVI-VAC)

      Completed
      • COVID-19
      • SARS-CoV-2
      • COVI-VAC
      • London, United Kingdom
        HMR
      Jan 11, 2023

      SARS-CoV-2 Trial in United States (mRNA-1273.214, Placebo)

      Recruiting
      • SARS-CoV-2
      • mRNA-1273.214
      • Placebo
      • Madera, California
      • +21 more
      Jan 11, 2023

      SARS-CoV-2 Trial (LVRNA009, 0.9%NaCl)

      Not yet recruiting
      • SARS-CoV-2
      • LVRNA009
      • 0.9%NaCl
      • (no location specified)
      Jan 11, 2023

      SARS-CoV-2 Trial in United States (mRNA-1273, Placebo)

      Recruiting
      • SARS-CoV-2
      • mRNA-1273
      • +2 more
      • Banning, California
      • +48 more
      Jan 5, 2023

      Coronavirus Disease 2019 With Point-of-Care Ultrasonography

      Completed
      • Coronavirus Infection
      • +3 more
      • Point-of-Care Ultrasonography (POCUS)
      • Minneapolis, Minnesota
      • +1 more
      Jan 2, 2023

      SARS-CoV-2 Trial (SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo)

      Recruiting
      • SARS-CoV-2
      • SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
      • +2 more
      • Bengbu, Anhui, China
        First Affiliated Hospital Bengbu Medical College
      Jan 3, 2023

      SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA

      Active, not recruiting
      • SARS-CoV-2
      • SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
      • +2 more
      • Bengbu, Anhui, China
        First Affiliated Hospital Bengbu Medical College
      Jan 3, 2023

      SARS-CoV-2 Trial in Bengbu (COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose, COVID-19 Variant (Omicron BA.5) mRNA Vaccine

      Recruiting
      • SARS-CoV-2
      • COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose
      • +2 more
      • Bengbu, Anhui, China
        First Affiliated Hospital Bengbu Medical College
      Jan 3, 2023

      COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)

      Enrolling by invitation
      • SARS-CoV-2
      • 20 μg dose of SYS6006 ;30 μg dose of SYS6006
      • Placebo
      • Nanjing, Jiangsu, China
      • +1 more
      Dec 20, 2022

      COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)

      Enrolling by invitation
      • SARS-CoV-2
      • 20 μg dose of SYS6006;30 μg dose of SYS6006
      • Placebo
      • Nanjing, Jiangsu, China
      • +1 more
      Dec 20, 2022

      Lung Transplant Recipient, SARS-CoV-2, Immunosuppression Trial (mRNA-1273 (Moderna COVID-19 vaccine))

      Active, not recruiting
      • Lung Transplant Recipient
      • +2 more
      • mRNA-1273 (Moderna COVID-19 vaccine)
      • Los Angeles, California
        UCLA Clinical Translational Research Center
      Dec 13, 2022

      SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high

      Not yet recruiting
      • SARS-CoV-2
      • SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
      • +2 more
      • (no location specified)
      Dec 1, 2022

      SARS-CoV-2 Trial in United States (mRNA-1273.211, mRNA-1273, mRNA-1273.617.2)

      Active, not recruiting
      • SARS-CoV-2
      • mRNA-1273.211
      • +6 more
      • Sacramento, California
      • +22 more
      Nov 16, 2022